group, with greater suppression in the InAs group. The serum indium concentration in the InAs group was about twice as high as that in the InP group, in each period.
Histopathologically, severe pulmonary inflammation and localized lesions with bronchiolo alveolar cell hyperplasia were present in both InAs and InP groups from just after the last administration. The localized lesions gradually transformed to proteinosis like lesions with periodic acid Schiff reagent positive exudation after 16 wk. By means of immunostaining of proliferating cell nuclear antigen and argyrophilic proteins associated with nucleolar organizer regions staining, proliferative activities were evidenced in the localized lesions at each time and were noticeable in their early stage. K-ras, a known oncogene, was not mutated in association with these lesions. In conclusion,
InAs and InP particles caused severe systemic toxicity and pulmonary localized hyperplastic lesions with proliferative activity were derived via the respiratory route. Neoplastic change was nil even in a 2-yr observation period. Key words: semiconductor materials, indium arsenide, indium phosphide, intratracheal instillation, pulmonary toxicity, proliferative activity Indium arsenide (InAs) and indium phosphide (InP) belong to the III-V semiconductor compounds that are widely used in the semiconductor industry as they possess superior electronic properties'''-'. With increasing use of these materials, health hazards to workers at semiconductor factories as well as environmental pollution have to be given attention. In the case of workers, the primary route of exposure would be direct inhalation. Chronic toxicity may be an urgent health hazard to be addressed because exposure to such materials may lead to accumulation in the body. There are numerous data on laboratory animals concerning the toxicity of gallium arsenide (GaAs), one of the most widely used semiconductor material S3-61 and data on the biological effects of InAs'' " and InPy-121 have recently appeared.
When the biological effects of semiconductor compounds are assessed, the toxicity of arsenic has been mainly focused on, whereas constitutive elements are considerably related to the effects and it is necessary to investigate their toxicities. We investigated a subacute toxicity of 7.7 mg/kg of InAs and GaAs and 1.3 mg/kg of arsenic trioxide (As,O3) by repeated intratracheal instillation of these agents into Syrian golden hamsters for 7 or 8 wk'3 "'. Pulmonary inflammation was severe and localized lesions of bronchiolo-alveolar cell hyperplasia with metaplasia and squamous cell hyperplasia were frequent in the lungs of InAs-treated hamsters but not in GaAs or As,O;-treated hamsters. We therefore considered that indium, not arsenic, probably accounted for most of the changes in the lungs. To elucidate which element, indium or arsenic, plays the main role in long-term systemic and pulmonary toxicity of InAs, equimolar InP was also used. We focused on the characterization of pulmonary hyperplastic lesions, especially proliferation and neoplastic potency. InAs was given at about half the dose used in the earlier studies because severe emaciation occurred and long-term observation was not feasible''. This is the first report on the long term biological effects of indium compounds instilled intratracheally.
Materials and Methods

Test materials
InAs and InP, over 99.99% pure and provided by Mitsuwa Chemicals (Osaka, Japan) were finely pulverized in an agate mortar and the mean count diameter for InAs and InP was 1.58p-n [6g (geometric standard deviation): 2.15] and 1.061an [6g: 1.80 ]. Both powders were analyzed in an energy dispersive X-ray fluorescence element analyzer (MESA-500, Horiba, Ltd., Kyoto, Japan). InAs powder contained 0.01 % (wt%) of zirconium and 0.01 % of yttrium, and InP powder contained 0.01 % of zirconium and a trace amount of yttrium. In particulate form, these compounds were suspended aseptically in pathogen-free 0.025 M phosphate buffer solution (PBS), pH 6.86 just before each instillation.
Animals
Weanling male 6 week-old Syrian golden hamsters were purchased from Japan SLC, Inc., (Shizuoka, Japan) and housed under conditions of controlled temperature of between 22 and 25°C. All the animals were maintained on a cycle of 12-h lighting conditions in a specific pathogen-free laboratory room of the Laboratory of Animal Experiments, Faculty of Medicine, Kyushu University. Four hamsters were housed in one stainless cage with diets (CE-2 pellets, Clea Japan, Inc., Tokyo, Japan) and tap water freely available. After they had acclimated to the animal facility for 2 wk before the start of the experiment, 144 eight week-old hamsters, with a mean ± SD weight of 110.87 ± 7.22 g, were randomized into 3 groups by weight: the InAs group, the InP group and the control group. There was no significant difference in body weight among groups at the start of the experiment.
Intratracheal instillation of materials
The concentrations of InAs and InP suspensions were 2.0 mg/ml and 1.5 mg/ml, respectively. As a single dose, each group was given an intratracheal instillation in a volume of 2.0 ml/kg suspension, containing equimolar particles, 21.08 ,umol/kg of InAs (4.0 mg/kg) or 20.58 pmol/kg of InP (3.0 mg/kg), whereas the control group were given PBS only. For the intratracheal instillations, we used the methods of Ishinishi et al."' Before each instillation, the hamsters were given 0. 1 ml of atropine sulfate subcutaneously and anesthetized inside a desiccator filled with diethyl ether gas. Suspensions of particles were instilled into the trachea of the hamsters by means of a microsyringe with a special metal needle. The hamsters were thus treated twice weekly for 8 wk.
Autopsy of'animals and tissue sampling After 0, 8, 16, 40, 64 and 88 wk of treatment, 4-8 hamsters in each group were weighed and deeply anesthetized with ether. Total blood taken from the posterior vena cava was centrifuged into serum. Resected lungs were weighed and fixed in 10% neutral buffered formalin for 20 to 24 h and processed in paraffin. Specimens were cut at a thickness of 6 ,um and mounted on microscopic glass slides. Each section was stained with hematoxylin and eosin and periodic acid Schiff reagent (PAS). When localized lesions of bronchiolo alveolar cell hyperplasia were evident, the same sections were newly cut and assessed, for proliferating cell nuclear antigen (PCNA), argyrophilic proteins associated with nucleolar organizer regions (AgNORs) and the mutation status of the K-ras gene.
Quantifying
of indium and arsenic in the sera by inductively coupled plasma mass spectrometrv (ICP-MS) Serum samples were stored at 80°C until analysis. They were prepared for analyis by diluting a 200 pl sample with 9.8 ml of 0.4% HNO3. Each sample contained yttrium at 20 ng/ml as an internal standard. Indium and arsenic were quantified for all samples with aqueous standard solutions in 0.4% HNO3 with ELAN 5000 ICP-MS (Perkin Elmer Japan).
Immunohistochemical staining of PCNA Selected tissue sections containing pulmonary localized lesions were stained for PCNA"', by a standard immunoperoxidase method and the avidin-biotin peroxidase complex ",'91. Monoclonal mouse anti-PCNA antibody (PC 10, Santa Cruz Biotechnology, Inc., California, USA) was used for detection of the antigen at 1:100 dilution, overnight at 4°C. Staining was completed with a 5-min incubation in the substrate 0.03% 3, 3' diaminobenzidine in 0.05 M Tris buffer (pH 7.6) containing 0.04% hydrogen peroxide. Immunostaining was interpreted independently by two different observers. Expression of PCNA was confined to the nuclei of the localized lesions and nuclear stainings were scored based on the labeling index (L.I.)-0'.
AgNORs staining
Pulmonary localized lesions were also stained for AgNORs, as described 211. Discrete dots in at least 100 cells in each lesion 22, 23, were counted and scored based on the average. As a control, we evaluated the AgNORs count of normal alveolar epithelium in the lungs of the control group. DNA extraction fio,ii specimens on slides and PCR with designed restriction fragm ent polymorphism (RFLP) analysis to detect K-ras mutation Pulmonary localized lesions were collected from paraffinized mounted sections, by a microdissection technique,'. The materials collected were digested with proteinase K to extract DNAs. The final concentrations of samples were at least 100 cells/p/. Mutations in codons 12 and 13 of the K-ras gene were examined by hemi-nested PCR methods24' 21". The first PCR reaction was performed in a 50 p1 reaction mixture containing 5 p1 template DNA prepared as above. The first PCR product was diluted 1:50 in distilled deionized water and 1 pl of the dilution was used as a template in a 20 p1 reaction mixture of the second PCR. The primers were previously designed 21.25, to establish new restriction sites into the final PCR product derived from a wild-type allele. Fifteen pl of the second PCR product was digested with 8-10 units of one of the specific restriction enzymes, BstNI for codon 12 and BglI for codon 13, under conditions recommended by the suppliers (NEW ENGLAND BioLabs Inc., Beverly, USA). The digested products were always run with lymphocytes collected individually and simultaneously, as negative controls, and complete digestion was confirmed. The final products were electrophoresed with 100 base DNA ladder (Takara BIOCHEMICALS, Shiga, Japan) and visualized by UV light after ethidium bromide staining. As mutant alleles were not digested by specific restriction enzymes, they appeared larger than the digested wild-type bands.
Statistical analysis
Data on body weight were analyzed by repeated measure-ANOVA.
Data on serum concentration of materials and proliferating levels were analyzed by the Mann-Whitney Test. A p-value below a level of 0.05 was considered to have statistical significance. Data are given as the mean ± standard deviation (SD).
Results
Systemic effects
Sixteen intratracheal instillations led to a mean total amount of particles per animal of 7.89 ± 0.58 mg in the InAs group and 6.04 ± 0.40 mg in the InP group, containing 4.77 ± 0.35 mg and 4.75 ± 0.32 mg of indium, respectively.
No hamsters died during the administration period and animals which died during the observation period were excluded from all evaluations.
In the control group, 4 were killed accidentally and 4 were cannibalized. Five died of emaciation and 3 were cannibalized in the InAs group and 3 of emaciation in the InP group. Finally, 40 animals in the control group, 40 in the InAs group and 45 in the InP group were examined, as scheduled. At least 4 hamsters in each group were examined at each time during the experiment.
Intratracheal instillations of InAs and InP led to a marked suppression of body weight gain. Fig. I A shows the body weight of whole animals during the administration period. The body weight of the InAs and InP groups gradually decreased from 5 wk of the administration period and the InAs group showed a greater inhibition of body weight gain than did the InP group. Significant differences in trends of body weight change were found between groups. Trends in body weight change throughout the observation period are shown in Fig. 1 B, for animals observed until 88 wk (5 animals in the InAs group, 4 in the InP group and 4 in the control). The difference in trends of body weight changes between the InAs group and the control group was significant (p<0.0001). Eight wk after the end of treatment, body weight in the InAs group once decreased to 122.24 ± 21.11 g, then increased slowly to the maximum level of 135.78 ± 24.03 g at 16 wk, that is 82.76% of the control group, and soon decreased in parallel to that of the control group. The difference in trends of body weight change between the InP group and the control group was also significant (p<0.05). Weight reduction in the InP group was less than in the InAs group (p<0.0001), the maximum level being 154.33 ± 13.56 g at 16 wk, that is 94.07% of the control group. Although reduction in body weight and emaciation occurred in both InAs and InP groups, no systemic signs such as respiratory distress, dermatologic abnormality, behavioral or neurological disorder were observed.
Serum levels of indium and arsenic
Serum concentrations of indium and arsenic are shown in Fig. 2 . At the termination of all instillations, serum indium levels were 7.62 ± 1.43 pM and 3.17 ± 0.56 pM in the InAs and InP groups, respectively.
The serum concentration of indium in the InAs group was about twice as high as that in the InP group, in each period, the difference being significant (p<0.0001). Indium was not detected in the sera of the control group. Serum indium had a biphasic pattern with an initial fast component and a subsequent slower component in both InAs and InP groups. The biological half-life of serum indium in the InAs group was 2.5 wk for the fast component, and 60.8 wk for the slower component. As for the InP group, the half-life was 6.2 wk for the fast component and 60.0 wk for the slower component.
In the InAs group, the serum arsenic concentration was continuously about 0.4 pM from 0 to 88 wk after treatment. In the InP and control groups, serum arsenic concentrations were very low, 0.05 ± 0.01 uM and 0.04 ± 0.00 pM, respectively.
Histopathological changes in the lungs
Absolute lung weights of both InAs and InP groups were significantly higher than that of the control group at each time of measurement (data not shown). The severity of pathologic change in the lungs is shown in (Fig. 3D) . Findings of neoplastic changes were nil throughout the experiment. Proliferative activity of pulmonary localized hyperplastic lesions Proliferating changes were evaluated with two known markers (Fig. 4) . Expressions of the PCNA protein were evident on the nuclei of bronchiolo-alveolar cells, mostly in the localized hyperplastic lesions and sparsely in the severely inflamed areas. As in the inflamed areas, L.I. of PCNA varied according to the severity of the inflammation, and could not be evaluated to compare with the L.I. of localized lesions. In both the InAs and InP groups. L.I. was significantly higher in the localized lesion than in normal tissue all the time, but gradually diminished. AgNORs counts for the localized lesions in both InAs and InP groups were significantly higher than for normal tissues of the control group all the time and tended to decrease with time. Between the InAs group and InP group, differences in neither PCNA L.I. nor AgNORs were significant in each period.
When we evaluated the genomic mutation of codons 12, 13 of the K-ras gene in DNAs isolated from the microdissected samples of all the pulmonary localized lesions of InAs and InP-treated hamsters, no mutation in any codon of the K-ras gene was evident in any of the lesions examined (Fig. 5 ).
Discussion
In a previous work. 14 times we instilled 7.7 mg/kg InAs intratracheally into hamsters, which could not be observed for more than 2 months because of severe emaciation'".
We set the instillation dose of indium particles at about a half the dose used in the last work for the present study and this is apparently the first report to evaluate the long-term systemic and pulmonary toxicity of indium compounds. Indium was readily detected in sera of hamsters in both InAs and InP groups.
In the InAs group, serum concentrations of indium just after instillation were 7.62 ± 1.43 pM. Whereas in our previous study, in which about twice the dose of InAs was instilled intratracheally, 19.47 ± 6.54 pM of indium was detected in the sera''. These results suggest that instilled InAs particles dissolve into serum in a dose dependent manner. Serum indium in both groups had a biphasic excretion pattern after intratracheal instillation of particles. Concerning the second component of serum indium, indium is eliminated slowly from the serum and remains long in the body.
Chronic effects on the body must be given attention to if exposed to these particles. 
